G8 Countries Generics Market Summary, Competitive Analysis and Forecast to 2027
Summary
The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
G8 countries contributed $149,123.6 million in 2022 to the global generics industry, with a compound annual growth rate (CAGR) of 5.3% between 2018 and 2022. The G8 countries are expected to reach a value of $194,881.1 million in 2027, with a CAGR of 5.5% over the 2022-27 period.
Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $69,916.7 million in 2022. This was followed by Germany and the UK, with a value of $25,152.7 and $15,416.4 million, respectively.
The US is expected to lead the generics industry in the G8 nations with a value of $82,184.5 million in 2016, followed by Germany and the UK with expected values of $33,999.8 and $23,214.8 million, respectively.
Scope
Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 generics market
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market
Leading company profiles reveal details of key generics market players’ G8 operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts by both value and volume
Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country
Reasons to Buy
What was the size of the G8 generics market by value in 2022?
What will be the size of the G8 generics market in 2027?
What factors are affecting the strength of competition in the G8 generics market?
How has the market performed over the last five years?
How large is the G8 generics market in relation to its regional counterparts?